FATE News and Press, Fate Therapeutics Inc. From 02/02/22

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, to...

If you believe in the January Barometer theory -- that returns in the first month of the year are a bellwether for performance for the rest of the year -- then biotech investors better buckle their seatbelts. The iShares Nasdaq Biotechnology ETF (IBB +1.2%) finished off last month with a ...

Multiplexed-engineered CAR NK Cell Product Candidate derived from Clonal Master iPSC Line that incorporates Four Functional Elements, including a Novel CAR Targeting the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Antigen Binding Domain of FT536 has been Shown...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in assets under management. After the Q3-2021 13F filings the consensus holdings were updated, 5 stocks were removed and 5 added from the un...

Wedbush analyst David Nierengarten has raised Fate Therapeutics (FATE +1.7%) shares to Outperform from Neutral, citing recent data presented for the company’s off-the-shelf natural killer (NK) cell product candidates, FT516 and FT596. At the 63rd American Society of Hematology (ASH) An...

Shares of Fate Therapeutics (NASDAQ:FATE) are up 5% after hours after presenting interim, early-stage data from FT596, an off-the-shelf, iPSC-derived natural killer ("NK") cell candidate for B-cell lymphoma. Five of six patients achieved a complete response with a single dose (...

5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab 13 of 19 Patients Achieve Objective Response with Single Dose of FT596 at 90 Million and 300 Million Cell Dose; 1...

6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million FT516 Cells per Dose 3 of 8 Patients Previously Treated with Autolo...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q3-2021 13F filings, the consensus holdings were updated, 5 stocks were removed and 5 added from the univ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...